Top Markets
Coin of the day
PreveCeutical Medical Inc. PreveCeutical Medical Inc.

PreveCeutical Medical Inc.

PREV
Classement en actions #33933
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating... PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Prix de l'action
$0.01100905
Dernière synchronisation: 2026-08-13
Capitalisation boursière
$6.59M
Changement (1 jour)
0.00%
Changement (1 an)
-49.29%
Pays
CA
Échange PreveCeutical Medical Inc. (PREV)

Catégorie

Bénéfices pour PreveCeutical Medical Inc. (PREV)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de PreveCeutical Medical Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour PreveCeutical Medical Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE